Incyte Q4 2021 Earnings Report
Key Takeaways
Incyte reported a 20% increase in total product and royalty revenues to $813 million for Q4 2021, driven by robust demand for Jakafi, continued uptake of Pemazyre, and a rapidly growing royalty revenue stream. The company also saw a successful U.S. launch of Opzelura with nearly 19,000 patients treated since launch.
Total product and royalty revenues increased by 20% to $813 million in Q4 2021.
Jakafi net product revenues grew by 15% to $592 million in Q4 2021.
Successful U.S. launch of Opzelura with nearly 19,000 patients treated from launch through the end of the year.
Vitiligo is the next substantial growth opportunity for ruxolitinib cream – under Priority Review in the U.S. and under review in Europe.
Incyte
Incyte
Incyte Revenue by Segment
Incyte Revenue by Geographic Location
Forward Guidance
Incyte provided financial guidance for 2022, which does not include revenue from Opzelura or the impact of any potential future strategic transactions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income